Details for Patent: 8,795,741

Which drugs does patent 8,795,741 protect, and when does it expire?

Patent 8,795,741 protects INOMAX and is included in one NDA.

Protection for INOMAX has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has twenty-five patent family members in six countries.

Summary for Patent: 8,795,741

Patent landscape, scope, and claims:

Title:	Methods for treating patients who are candidates for inhaled nitric oxide treatment
Abstract:	Disclosed are methods of reducing the risk that a medical treatment comprising inhalation of nitric oxide gas will induce an increase in pulmonary capillary wedge pressure in the patient, leading to pulmonary edema.
Inventor(s):	Baldassarre; James S. (Doylestown, PA)
Assignee:	INO Therapeutics LLC (Hampton, NJ)
Application Number:	13/683,417
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,795,741
Patent Claim Types: see list of patent claims	Use; Process;

Drugs Protected by US Patent 8,795,741

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Mallinckrodt Hosp	INOMAX	nitric oxide	GAS;INHALATION	020845-002	Dec 23, 1999		DISCN	Yes	No					Y
Mallinckrodt Hosp	INOMAX	nitric oxide	GAS;INHALATION	020845-003	Dec 23, 1999	AA	RX	Yes	Yes					Y

International Family Members for US Patent 8,795,741

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2009202685
Australia	2010202422
Australia	2010206032